A Phase I Dose Per Fraction Escalation Study of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining With Temozolomide (TMZ) Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM).
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 06 Sep 2016 Status changed from active, no longer recruiting to completed.
- 15 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2018.
- 15 Apr 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2018.